Trial Profile
Pharmacokinetics and safety of ceftolozane/tazobactam in haemodialysis patients with severe renal impairment or end-stage renal disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2014
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Cubist Pharmaceuticals
- 20 Feb 2014 New trial record